Can and Should Value Based Pricing Be Applied to Molecular Diagnostics?

Medientyp: E-Book

Titel: Can and Should Value Based Pricing Be Applied to Molecular Diagnostics?

Beteiligte: Garau, Martina [Verfasser:in]; Towse, Adrian [Sonstige Person, Familie und Körperschaft]; Garrison, Louis [Sonstige Person, Familie und Körperschaft]; Housman, Laura [Sonstige Person, Familie und Körperschaft]; Ossa, Diego [Sonstige Person, Familie und Körperschaft]

Erschienen: [S.l.]: SSRN, [2015]

Umfang: 1 Online-Ressource (27 p)

Sprache: Englisch

DOI: 10.2139/ssrn.2633990

Identifikator:

Entstehung:

Anmerkungen: Nach Informationen von SSRN wurde die ursprüngliche Fassung des Dokuments April 1, 2012 erstellt

Beschreibung: Current pricing and reimbursement systems for diagnostics are not efficient. Prices for diagnostics often are driven by administrative practice and expected production cost. The purpose of this paper is to discuss how a value based pricing (VBP) framework that is being used to ensure efficient use and price of medicines also could be applied to diagnostics. Diagnostics not only facilitate health gain and cost savings, but also provide information to inform patients' decisions on interventions and their future “behaviours”. For value assessment processes, we recommend a two‐part approach.Companion diagnostics introduced at the launch of the drug should be assessed through new drug assessment processes considering a broad range of value elements and a balanced analysis of diagnostic impacts. A separate diagnostic‐dedicated committee using VBP principles should review other diagnostics lying outside the companion diagnostics‐and‐drug “at‐launch” situation

Zugangsstatus: Freier Zugang

Nur in Feld suchen:

Zuletzt gesuchte Begriffe: